Tonner Elizabeth, Barber Michael C, Allan Gordon J, Beattie James, Webster John, Whitelaw C Bruce A, Flint David J
Hannah Research Institute, Ayr KA6 5HL, England, UK.
Development. 2002 Oct;129(19):4547-57. doi: 10.1242/dev.129.19.4547.
We have previously demonstrated that IGFBP-5 production by mammary epithelial cells increases dramatically during involution of the mammary gland. To demonstrate a causal relationship between IGFBP-5 and cell death we created transgenic mice expressing IGFBP-5 in the mammary gland using a mammary-specific promoter, beta-lactoglobulin. DNA content in the mammary glands of transgenic mice was decreased as early as day 10 of pregnancy. Histological analysis indicated reduced numbers of alveolar end buds, with decreased ductal branching. Transgenic dams produced IGFBP-5 in their milk at concentrations similar to those achieved at the end of normal lactation. Mammary cell number and milk synthesis were both decreased by approximately 50% during the first 10 days of lactation. BrdU labelling was decreased, whereas DNA ladders were increased in transgenic animals on day 1 of lactation. On day 2 postpartum, the epithelial invasion of the mammary fat pad was clearly impaired in transgenic animals. The concentrations of the pro-apoptotic molecule caspase-3 and of plasmin were both increased in transgenic animals whilst the concentrations of 2 prosurvival molecules Bcl-2 and Bcl-x(L)were both decreased. In order to examine whether IGFBP-5 acts by inhibiting the survival effect of IGF-I we examined IGF receptor phosphorylation and Akt phosphorylation and showed that both were inhibited. We attempted to "rescue" the transgenic phenotype by using growth hormone to increase endogenous IGF-I concentrations or by implanting minipumps delivering an IGF-1 analogue, R(3)-IGF-1, which binds weakly to IGFBP-5. Growth hormone treatment failed to affect mammary development suggesting that increased concentrations of endogenous IGF-1 are insufficient to overcome the high concentrations of IGFBP-5 produced by these transgenic animals. In contrast mammary development (gland weight and DNA content) was normalised by R3-IGF-I although milk production was only partially restored. This is the first demonstration that over-expression of IGFBP-5 can lead to; impaired mammary development, increased expression of the pro-apoptotic molecule caspase-3, increased plasmin generation and decreased expression of pro-survival molecules of the Bcl-2 family. It clearly demonstrates that IGF-I is an important developmental/survival factor for the mammary gland and, furthermore, this cell death programme may be utilised in a wide variety of tissues.
我们之前已经证明,在乳腺退化过程中,乳腺上皮细胞产生的IGFBP - 5会显著增加。为了证明IGFBP - 5与细胞死亡之间的因果关系,我们使用乳腺特异性启动子β - 乳球蛋白,创建了在乳腺中表达IGFBP - 5的转基因小鼠。早在怀孕第10天,转基因小鼠乳腺中的DNA含量就降低了。组织学分析表明,肺泡末端芽数量减少,导管分支减少。转基因母鼠乳汁中产生的IGFBP - 5浓度与正常泌乳末期达到的浓度相似。在泌乳的前10天,乳腺细胞数量和乳汁合成均减少了约50%。在泌乳第1天,转基因动物的BrdU标记减少,而DNA梯带增加。产后第2天,转基因动物乳腺脂肪垫的上皮侵袭明显受损。转基因动物中促凋亡分子caspase - 3和纤溶酶的浓度均升高,而两种抗生存分子Bcl - 2和Bcl - x(L)的浓度均降低。为了研究IGFBP - 5是否通过抑制IGF - I的生存作用发挥作用,我们检测了IGF受体磷酸化和Akt磷酸化,结果表明二者均受到抑制。我们试图通过使用生长激素提高内源性IGF - I浓度,或植入输送IGF - 1类似物R(3)-IGF - 1(其与IGFBP - 5结合较弱)的微型泵来“挽救”转基因表型。生长激素治疗未能影响乳腺发育,这表明内源性IGF - 1浓度的增加不足以克服这些转基因动物产生的高浓度IGFBP - 5。相比之下,R3 - IGF - I使乳腺发育(腺体重量和DNA含量)恢复正常,尽管乳汁产量仅部分恢复。这首次证明了IGFBP - 5的过表达可导致乳腺发育受损、促凋亡分子caspase - 3表达增加、纤溶酶生成增加以及Bcl - 2家族抗生存分子表达减少。这清楚地表明IGF - I是乳腺重要的发育/生存因子,此外,这种细胞死亡程序可能在多种组织中发挥作用。